Rybka Justyna, Butrym Aleksandra, Wróbel Tomasz, Jaźwiec Bożena, Stefanko Ewa, Dobrzyńska Olga, Poręba Rafał, Kuliczkowski Kazimierz
Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, ul. Pasteura 4, 50-367, Wrocław, Poland,
Med Oncol. 2014 Dec;31(12):319. doi: 10.1007/s12032-014-0319-7. Epub 2014 Nov 22.
Toll-like receptors play an important role in the host defense against microorganisms. Sepsis remains a common cause of mortality in patients with acute myeloid leukemia (AML) treated with intensive induction chemotherapy. The expression of TLRs and their association with the development of sepsis in patients with acute myeloid leukemia remains unclear. The aim of this study was to investigate the associations between expression of TLR2, TLR4 and TLR9 and occurrence of sepsis in patients treated with intensive induction chemotherapy for AML. A total of 103 patients with newly diagnosed AML were evaluated. Bone marrow samples were taken before induction therapy. Using quantitative reverse transcriptase PCR, the mRNA expression of genes TLR2, TLR4 and TLR9 was measured. Neutropenic fever occurred in 98 patients. We identified 20 episodes of severe sepsis (20%). In patients with neutropenic fever, the mRNA expression of TLR2 and TLR4 was significant higher in septic patients than in patients without sepsis symptoms (ΔCt TLR2 0.93 ± 0.82 vs 0.78 ± 0.85 and ΔCt TLR4 0.38 ± 0.29 vs 0.34 ± 0.25). Moreover, we observed that expression of TLR2 and TLR4 was significantly higher in patients with AML and bacterial infection in comparison with group with separate fungal infection (ΔCt TLR2 1.15 ± 1.06 vs 0.66 ± 0.51 and ΔCt TLR4 0.45 ± 0.38 vs 0.21 ± 0.19). Our results suggest that TLRs could be an independent factor for the development of sepsis in patients with acute myeloid leukemias after intensive induction chemotherapy. This observation should be validated by larger study.
Toll样受体在宿主抵御微生物的防御中发挥重要作用。脓毒症仍然是接受强化诱导化疗的急性髓系白血病(AML)患者死亡的常见原因。急性髓系白血病患者中Toll样受体的表达及其与脓毒症发生的关联仍不清楚。本研究的目的是调查接受AML强化诱导化疗患者中TLR2、TLR4和TLR9的表达与脓毒症发生之间的关联。共评估了103例新诊断的AML患者。在诱导治疗前采集骨髓样本。使用定量逆转录聚合酶链反应测量基因TLR2、TLR4和TLR9的mRNA表达。98例患者发生了中性粒细胞减少性发热。我们确定了20例严重脓毒症发作(20%)。在中性粒细胞减少性发热患者中,脓毒症患者的TLR2和TLR4的mRNA表达显著高于无脓毒症症状的患者(ΔCt TLR2 0.93±0.82对0.78±0.85,ΔCt TLR4 0.38±0.29对0.34±0.25)。此外,我们观察到与单独真菌感染组相比,AML合并细菌感染患者的TLR2和TLR4表达显著更高(ΔCt TLR2 1.15±1.06对0.66±0.51,ΔCt TLR4 0.45±0.38对0.21±0.19)。我们的结果表明,Toll样受体可能是强化诱导化疗后急性髓系白血病患者发生脓毒症的独立因素。这一观察结果应通过更大规模的研究进行验证。